Wen Chen Yeh

Chief Tech/Sci/R&D Officer presso Surrozen Operating, Inc.

61 anni

Health Technology

Consumer Services

Profilo

Wen Chen Yeh is currently the Chief Scientific Officer at Surrozen Operating, Inc. He previously worked at Amgen, Inc. as a Scientific Executive Director from 2006 to 2016.
He also worked as a Professor at the University of Toronto.
In addition, he was the former Chief Scientific Officer at Surrozen, Inc. from 2016 to 2023.
Mr. Yeh holds a doctorate degree from The Johns Hopkins University and National Taiwan University.

Posizioni attive di Wen Chen Yeh

Società	Posizione	Inizio
Surrozen Operating, Inc. Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA.	Chief Tech/Sci/R&D Officer	01/05/2016

Tutte le posizioni attive di Wen Chen Yeh

Precedenti posizioni note di Wen Chen Yeh

Società	Posizione	Fine
SURROZEN, INC.	Chief Tech/Sci/R&D Officer	31/07/2023
AMGEN INC.	Chief Tech/Sci/R&D Officer	01/04/2016
University of Toronto	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Wen Chen Yeh

Formazione di Wen Chen Yeh

The Johns Hopkins University	Doctorate Degree
National Taiwan University	Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Wen Chen Yeh

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
AMGEN INC.	Health Technology
SURROZEN, INC.	Health Technology

Aziende private	1
Surrozen Operating, Inc. Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA.	Health Technology